Worldwide, 1.5 million men are diagnosed with prostate cancer each year, according to AngioDynamics. NanoKnife essentially uses special probes that act as electrodes and are inserted into cancer ...

A highly expensive, revolutionary treatment for recurrent prostate cancer is for the first time in Australia available at a ...

AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target and destroy tissue without delivering excess heat and the unintended ...

Prostate cancer is the second most common cancer in men worldwide, with approximately 1.5 million new cases diagnosed annually.2 Many of these patients seek alternatives to radical procedures that ...

AngioDynamics has teamed up with the University College London Hospital (UCLH) in the UK to launch a prospective registry study evaluating the long-term effects of the NanoKnife system for ...

This is used by NanoKnife to specifically key in on the tumor, instead of impacting the prostate gland overall. "Prostate cancer is the most common cancer in men, and there is a very wide disease ...

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for ...

LITTLE ROCK, Ark. — A Little Rock grandfather is back to living life on his terms after becoming the very first patient in Arkansas to receive groundbreaking treatment for prostate cancer. "I've ...

NanoKnife is also being evaluated in the PRIS clinical trial (NCT05513443), which is enrolling 184 prostate cancer patients to assess the feasibility of treating localised prostate cancer using IRE.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment ...